June 03, 2025 01:00 ET | Source: Addex Therapeutics Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and…
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing…
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of…